Mount Sinai Licenses SARS-COV-2 Antibody to Sorrento Therapeutics Which Prepares for IND in Anticipation of Phase I Clinical Trial by Q3

Mount Sinai Health System (“Mount Sinai”) and Sorrento Therapeutics (Nasdaq: “SRNE,” “Sorrento”) have inked a deal to investigate an antibody cocktail called COVI-SHIELD™ that potentially can treat COVID-19 patients. This investigational product leverages the work...